CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUP

这是一项建立计划中的NIDA国家药物滥用治疗临床试验网络的中大西洋区域节点的建议。 这个中大西洋地区包括马里兰州、弗吉尼亚州和华盛顿，华盛顿特区，该项目涉及该地区主要大学（约翰霍普金斯大学医学院、弗吉尼亚联邦大学、马里兰州大学）之间的合作努力以及各种社区药物滥用治疗方案。 这些社区治疗计划为大量人口统计学，诊断和综合征多样性的药物滥用患者提供临床研究，以及代表其治疗服务提供的类型，方式和重点的多样性的治疗计划。 这些学术和社区治疗计划已经建立了强有力的合作关系，并共同致力于系统的社区研究，将评估不同药物滥用治疗和服务的有效性，直接在社区治疗计划，并将评估和研究相关的因素采用改进的治疗，在RFA的要求。 学术中心在进行和管理药物滥用治疗的对照临床试验方面拥有丰富的经验和专业知识，包括行为治疗和药物治疗，以及综合行为药物治疗，用于各种不同类型的物质使用障碍（海洛因，可卡因，镇静剂，酒精，烟草）。 这些中心在社区治疗项目的培训、实施和评估方面也有丰富的经验和专业知识。 该合作小组建议参加NIDA临床试验网络，在社区诊所进行行为和/或药物滥用治疗的对照试验，并调查社区诊所采用新治疗方法的过程和影响。 该计划将与巴尔的摩、华盛顿和里士满的药物治疗计划和无毒品计划合作，并在这些计划中协调努力。

This is a proposal to create a Mid-Atlantic regional node of the planned NIDA National Drug Abuse Treatment Clinical Trials Network. This Mid-Atlantic region incorporates Maryland, Virginia, and Washington, D.C., and involves a collaborative effort among major universities in the region (Johns Hopkins University School of Medicine, Virginia Commonwealth University, University of Maryland) and a diverse array of community drug abuse treatment programs. These community treatment programs provide clinical research access to a large population of drug abuse patients with great demographic, diagnostic, and syndromal diversity, as well as to treatment programs representing great diversity in the types, modalities, and focus of their treatment service delivery. These academic and community treatment programs have established strong collaborative relations and are jointly committed to systematic community-based research that will assess the effectiveness of different drug abuse treatments and services directly in community treatment programs, and that will assess and study factors related to adoption of improved treatments, as requested in the RFA. The academic centers have extensive experience and expertise in conducting and managing controlled clinical trials of drug abuse treatments, including both behavioral treatments and pharmacological treatments, as well as integrated behavioral-pharmacological treatments, for a broad range of different types of substance use disorders (heroin, cocaine, sedatives, alcohol, tobacco). The centers also have extenisve experience and expertise in training, implementation, and assessment within community treatment programs. This collaborative group proposes to participate in the NIDA Clinical Trials Network, to conduct controlled trials of behavioral and/or pharmacological drug abuse treatments in community clinics, and to investigate the process of and influences on community clinic adoption of new treatments. The program will work with and coordinate efforts within both pharmacotherapy programs and drug-free programs in Baltimore, Washington, and Richmond.